We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out).

 

I'm ok with this

Grunenthal PRO - Your CMO+ Excellence for your products

At your service

Picking the right partner is everything: you need a guarantee of quality, excellent supply performance and a commitment to you, the client.

Our Global Operations team maintains six specialized plants on two continents. The plants in Germany, Switzerland, Italy, Ecuador and Chile operate as full-service CMOs vertically integrated from active substance to finished products with a strong service portfolio including controlled drugs handling, regulatory services, production process design, export into 100 countries worldwide and special technologies such as hormones, hot melt extrusion or biopharma packaging.

Together with all relevant services around an end-to-end supply chain they make sure our customers are satisfied in every way. How can our Global Operations team help you?

Manufacturing sites
6

operating in a global network

Global Production Network
1,400

employees worldwide with all their dedication

Products
3,800

covering various formulations

Countries
100

supplied with excellence

Proven quality for medical devices

We are committed to serving patients with products that improve their lives and health. To ensure this, Grünenthal is aiming for the safe, reliable and economical production and supply of high-quality pharmaceutical products.

Grünenthal’s quality management system has been certified against an important industry standard. We fulfil the criteria of DIN EN ISO 13485:2016 to manufacture medical devices and sell them in Europe.

The audit was conducted at our German site by a team from the TÜV-Rheinland LGA standards organization. The certificate is valid until mid of April 2021.